Eli Lilly and Company (NYSE:LLY) Shares Up 1% - Should You Buy?

Key Points

• Eli Lilly and Company shares rose 1% during trading, reaching a last price of $854.40, despite a 25% decline in trading volume compared to the average session.
• Recent analyst ratings show a mix of opinions, with Wall Street Zen downgrading the stock to a "buy" while Berenberg Bank reduced its target price to $830 and HSBC increased it to $800.
• The company reported a 37.6% year-over-year revenue increase in its latest quarterly earnings, with EPS of $6.31 exceeding analysts' estimates by $0.72.

Eli Lilly and Company (NYSE:LLY - Get Free Report)'s share price shot up 1% during trading on Thursday . The stock traded as high as $860.25 and last traded at $854.40. 3,062,232 shares traded hands during mid-day trading, a decline of 25% from the average session volume of 4,097,017 shares. The stock had previously closed at $845.72.

Analysts Set New Price Targets

LLY has been the subject of several recent analyst reports. Wall Street Zen lowered Eli Lilly and Company from a "strong-buy" rating to a "buy" rating in a report on Saturday, September 20th. Berenberg Bank reaffirmed a "hold" rating and issued a $830.00 target price (down from $970.00) on shares of Eli Lilly and Company in a report on Wednesday, September 17th. HSBC upped their target price on Eli Lilly and Company from $700.00 to $800.00 in a report on Wednesday, October 1st. DZ Bank raised Eli Lilly and Company from a "hold" rating to a "strong-buy" rating in a report on Thursday, August 14th. Finally, Daiwa Capital Markets lowered Eli Lilly and Company from an "outperform" rating to a "neutral" rating and set a $700.00 price objective for the company. in a report on Sunday, August 17th. One research analyst has rated the stock with a Strong Buy rating, fourteen have issued a Buy rating and ten have issued a Hold rating to the company's stock. Based on data from MarketBeat.com, the company has an average rating of "Moderate Buy" and an average target price of $948.56.

Eli Lilly and Company Stock Up 1.0%

The stock has a fifty day moving average price of $740.99 and a 200 day moving average price of $766.49. The company has a debt-to-equity ratio of 1.86, a current ratio of 1.28 and a quick ratio of 1.00. The stock has a market capitalization of $808.66 billion, a P/E ratio of 55.84, a price-to-earnings-growth ratio of 1.18 and a beta of 0.47.

Eli Lilly and Company (NYSE:LLY - Get Free Report) last posted its quarterly earnings results on Thursday, August 7th. The company reported $6.31 EPS for the quarter, topping analysts' consensus estimates of $5.59 by $0.72. Eli Lilly and Company had a return on equity of 92.72% and a net margin of 25.91%.The firm had revenue of $15.56 billion during the quarter, compared to analyst estimates of $14.40 billion. During the same period last year, the company earned $3.92 earnings per share. The business's revenue for the quarter was up 37.6% on a year-over-year basis. Eli Lilly and Company has set its FY 2025 guidance at 21.750-23.000 EPS. On average, research analysts forecast that Eli Lilly and Company will post 23.48 earnings per share for the current year.

Insider Transactions at Eli Lilly and Company

In other Eli Lilly and Company news, Director Jamere Jackson acquired 200 shares of the stock in a transaction that occurred on Friday, August 8th. The shares were bought at an average price of $639.56 per share, for a total transaction of $127,912.00. Following the completion of the transaction, the director owned 9,402 shares of the company's stock, valued at approximately $6,013,143.12. This represents a 2.17% increase in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink. Also, CEO David A. Ricks acquired 1,632 shares of the stock in a transaction that occurred on Tuesday, August 12th. The stock was acquired at an average price of $644.77 per share, for a total transaction of $1,052,264.64. Following the transaction, the chief executive officer directly owned 546,601 shares of the company's stock, valued at $352,431,926.77. This represents a 0.30% increase in their position. The disclosure for this purchase can be found here. Over the last ninety days, insiders purchased 4,514 shares of company stock valued at $2,894,841. 0.13% of the stock is currently owned by company insiders.

Institutional Investors Weigh In On Eli Lilly and Company

Institutional investors and hedge funds have recently made changes to their positions in the business. Brighton Jones LLC raised its position in Eli Lilly and Company by 22.0% during the fourth quarter. Brighton Jones LLC now owns 9,597 shares of the company's stock valued at $7,409,000 after purchasing an additional 1,730 shares in the last quarter. Revolve Wealth Partners LLC raised its position in Eli Lilly and Company by 2.8% during the fourth quarter. Revolve Wealth Partners LLC now owns 1,471 shares of the company's stock valued at $1,136,000 after purchasing an additional 40 shares in the last quarter. Wedge Capital Management L L P NC raised its position in Eli Lilly and Company by 13.9% during the first quarter. Wedge Capital Management L L P NC now owns 738 shares of the company's stock valued at $610,000 after purchasing an additional 90 shares in the last quarter. Covestor Ltd raised its position in Eli Lilly and Company by 24.9% during the first quarter. Covestor Ltd now owns 426 shares of the company's stock valued at $352,000 after purchasing an additional 85 shares in the last quarter. Finally, GAMMA Investing LLC raised its position in Eli Lilly and Company by 25.8% during the first quarter. GAMMA Investing LLC now owns 18,000 shares of the company's stock valued at $14,866,000 after purchasing an additional 3,696 shares in the last quarter. Hedge funds and other institutional investors own 82.53% of the company's stock.

Eli Lilly and Company Company Profile

Eli Lilly and Company discovers, develops, and markets human pharmaceuticals worldwide. The company offers Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, and Humulin U-500 for diabetes; Jardiance, Mounjaro, and Trulicity for type 2 diabetes; and Zepbound for obesity.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.